Blaize Seeks 1-for-10 to 1-for-35 Reverse Split to Cure Nasdaq Delisting Notice

summarizeSummary

Blaize's preliminary proxy asks shareholders to approve a 1-for-10 to 1-for-35 reverse split to cure its Nasdaq minimum-bid deficiency by March 29, 2027, using a new high-vote Series B Preferred to boost turnout, and re-proposes allowing director removal without cause.

check_boxKey Events · Corporate Governance and Compliance · BZAI

• Reverse Split Proposed to Cure Delisting

  The Board seeks authority for a 1-for-10 to 1-for-35 reverse split, with the ratio set at its discretion, to be effected no later than 2027; the Nasdaq notice was received September 28, 2026, and compliance must be regained by March 29, 2027.

• Series B Preferred Skews the Vote

  A dividend of 1/1,000th of a Series B Preferred share per common share (record date October 26, 2026) carries 1,000,000 votes per whole share on the reverse split and adjournment only; shares not represented at the meeting are automatically redeemed, so the proposal could pass with less than a majority of common shares outstanding.

• Authorized Shares Stay at 600 Million

  The split does not reduce the 600 million authorized common shares, so it effectively increases the unissued share pool available for future issuance.

• Director Removal Amendment Re-Proposed

  Would let shareholders remove directors with or without cause by majority vote, replacing the current for-cause, two-thirds standard; a similar proposal failed at the December 3, 2025 annual meeting.

auto_awesomeAnalysis · BZAI · Manufacturing

Blaize is asking shareholders to approve a reverse split of between 1-for-10 and 1-for-35 to lift the share price back above Nasdaq's $1.00 minimum after the October 2 delisting notice; the company has until March 29, 2027 to regain compliance. The mechanics matter as much as the split: a new Series B Preferred dividend gives each represented share 1,000 extra votes on the reverse-split proposal, so holders who actually vote effectively outvote those who don't, and the proposal can pass with less than a majority of common shares outstanding. The proxy also re-runs the director-removal amendment that failed in December 2025 and discloses a $2.57M share issuance to Chair Lane Bess's Bess Ventures to settle a dispute, alongside a third forbearance on the Sponsor's defaulted notes. With the stock at $0.24 and a going-concern warning already on file, the split is a listing-survival step, not a fix for the underlying business.